ALL
Pharma in China
Pharma Experts
Market News
Products Guide
Brand Story
-
Allogene Therapeutics to build out facility for allogeneic CAR T treatments
February 24, 2019Another CAR T production facility is slated for the U.S. as a biotech moves down the road with a bucket full of cash and a fist full of candidates. But unlike currently approved CAR T treatments, Allogene Therapeutics is looking to use donated T cells tha -
Ablexis Announces Licensing Agreement with Allogene Therapeutics
December 10, 2018Ablexis, LLC, a biopharmaceutical company focused on licensing its AlivaMab Mouse technology for antibody drug discovery, has announced a license agreement.... -
Allogene Therapeutics Presents Data from Preclinical Study of ALLO-715 (anti-BCMA) Demonstrating Allogeneic CAR T Potential in Multiple Myeloma at the 2018 ASH Annual Meeting
December 04, 2018Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) therapies for cancer, today announced results of a preclinical study of ALLO-715, an AlloCAR T therapy targeting -
Pfizer, Allogene Therapeutics Enter into Asset Contribution Agreement
April 09, 2018Pfizer and Heterologous Therapeutics Announce the Agreement between Pfizer and Allo-Chimeric Antigen Receptor T Cell (CAR T) Treatment Related Assets
Pharma Sources Insight January 2025
